CV Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Net Income (Loss) Per Share (Tables)

Net Income (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2023

Computation of Basic and Diluted Earnings per Share

The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share data):


	For the years ended December 31,
	2023		2022
Numerator:
Net income (loss) attributable to common stockholders	$	3,102	$	(9,134	)
Denominator for basic and diluted net income (loss) per share:
Weighted average common shares outstanding for basic		153,954		138,034
Dilutive potential common stock outstanding:
Stock options		1		—
Weighted average common shares outstanding for diluted		153,955		138,034
Basic net income (loss) per share attributable to common stockholders	$	0.02	$	(0.07	)
Diluted net income (loss) per share attributable to common stockholders	$	0.02	$	(0.07	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following common stock equivalents were not included in the calculation of net income (loss) per diluted share because their effect were anti-dilutive (in thousands):


	For the years ended December 31,
	2023		2022
Stock options		20,185		15,581
Performance stock options		11,000		11,000
Warrants		10,750		10,750
Total		41,935		37,331